Welcome to our dedicated page for Merus news (Ticker: MRUS), a resource for investors and traders seeking the latest updates and insights on Merus stock.
Merus N.V. (MRUS) generates frequent news as an oncology company focused on full-length human bispecific and trispecific antibody therapeutics, known as Multiclonics®. Its disclosures highlight clinical progress, regulatory designations, corporate transactions and collaboration updates that are relevant to investors and observers of the biotechnology sector.
A central theme in recent Merus news is the development of petosemtamab (MCLA-158), a Biclonics® antibody targeting EGFR and LGR5. Company announcements describe interim data from phase 2 trials in metastatic colorectal cancer, including combinations with FOLFOX and FOLFIRI and monotherapy in later-line settings, as well as data in recurrent or metastatic head and neck squamous cell carcinoma. News releases detail response rates, safety observations and presentations at major scientific meetings such as the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and the American Society of Clinical Oncology Annual Meeting.
Another important news stream concerns regulatory and strategic milestones. Merus has reported that the U.S. FDA granted Breakthrough Therapy Designation to petosemtamab in two head and neck cancer settings, and it has provided updates on phase 3 registration trials in first-line and later-line recurrent or metastatic HNSCC. In parallel, the company issues regular financial and business updates, including quarterly results, capital raises, and details on research collaborations with partners such as Incyte, Eli Lilly, Gilead, Ono and Biohaven.
Recent company announcements also cover the agreed acquisition of Merus by Genmab A/S through a cash tender offer and subsequent back-end transactions. Joint releases and 8-K filings describe the tender offer terms, acceptance levels, change of control and plans for a subsequent offering period. For users following MRUS news, this page offers a consolidated view of clinical, regulatory, financial and corporate developments, including the transition of Merus into an indirect wholly owned subsidiary of Genmab.
Merus N.V. (MRUS) reported Q3 2020 financial results, showing total revenue of $8.57 million, a slight increase from $8.15 million in Q3 2019. Collaboration revenue increased by $0.3 million, driven by higher Incyte reimbursements, while other revenues saw a decline. R&D expenses rose to $17.54 million due to increased costs related to their lead program, Zenocutuzumab (Zeno), which is in clinical trials for NRG1 fusion cancers. The company ended the quarter with $190.2 million in cash and expects this will fund operations into H2 2022.
myTomorrows and Merus are expanding their collaboration to enhance screening and recruitment for patients with neuregulin 1 (NRG1) fusion cancers. Under their 2019 agreement, myTomorrows has supported eligible patients in Merus’ Early Access Program for zenocutuzumab (Zeno). The new phase includes raising awareness of molecular screening for pancreatic cancer and increasing patient enrollment in Merus’ eNRGy clinical trial, aimed at assessing the safety and efficacy of Zeno in NRG1+ cancers.
Merus (Nasdaq: MRUS), a clinical-stage oncology company, announced that its President and CEO, Bill Lundberg, M.D., will present a company overview at the 2020 Wedbush PacGrow Healthcare Conference. The presentation is scheduled for August 12, 2020, at 10:20 a.m. ET.
A live webcast will be available on the company's website, along with an archived presentation for a limited time.
Merus specializes in developing innovative full-length multispecific antibodies, known as Biclonics® and Triclonics™.
Merus N.V. (MRUS) reported its Q2 2020 financial results, highlighting an extended cash runway into the second half of 2022. The company appointed Dr. Andrew Joe as Chief Medical Officer, enhancing its clinical development expertise. Collaboration revenue fell to $0.2 million, while total revenue decreased to $6.1 million. Research and development expenses increased by $2.9 million, driven by higher personnel and pre-clinical costs. The net loss rose to $17.9 million, and cash and cash equivalents decreased to $152.1 million, reflecting operational cash use.
Merus N.V. (Nasdaq: MRUS) has received Orphan Drug Designation from the FDA for Zenocutuzumab (Zeno), a bispecific antibody targeting pancreatic cancer. This designation highlights the unmet need for treatments in this area and offers potential benefits like grant funding and market exclusivity. Zeno has shown promise in early clinical trials for patients with NRG1 gene fusions, rare drivers of cancer growth. Merus is currently conducting a global Phase 1/2 clinical trial, the eNRGy trial, to assess Zeno's efficacy in NRG1+ cancers, including pancreatic and lung cancer.
Merus N.V. (Nasdaq: MRUS) has appointed Andrew Joe, M.D., as Chief Medical Officer, effective immediately. Dr. Joe has over 20 years of oncology drug development experience. He previously led immuno-oncology at Sanofi and contributed to significant approvals, including LIBTAYO and KEYTRUDA. At Merus, he will focus on advancing the clinical pipeline for multispecific antibodies, particularly Zenocutuzumab for NRG1 fusion cancers. This strategic appointment aims to enhance clinical execution and supports the company's personalized medicine approach.
Merus (Nasdaq: MRUS) collaborates with Caris Life Sciences to enhance patient identification for the Zenocutuzumab Phase 1/2 eNRGy trial focused on targeting NRG1 fusions in cancers such as pancreatic cancer. Caris will conduct whole exome and transcriptome sequencing to identify these fusions, potentially driving enrollment in the trial. The NRG1 fusion is a critical cancer growth factor, and Zeno is designed to inhibit its activity, offering promise for treating NRG1+ cancers. The collaboration aims to raise awareness and improve enrollment in the clinical trial.
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that CEO Bill Lundberg, M.D., will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 3, 2020, at 3:30 p.m. ET. A live webcast will be available on the company's website, with a replay accessible for a limited time post-event. Merus focuses on developing innovative full-length multispecific antibodies, known as Biclonics®, which demonstrate features similar to conventional human monoclonal antibodies, including a long half-life and low immunogenicity.
Merus N.V. (Nasdaq: MRUS) announces acceptance of six abstracts for the upcoming ASCO20 and EHA 2020 congresses. Key highlights include an independent epidemiology study reaffirming the clinical potential of zenocutuzumab (MCLA-128) in NRG1 fusion cancers and limited activity of MCLA-117 in AML trials. Zenocutuzumab has shown promise in NRG1+ pancreatic and lung cancers and will continue in clinical trials. MCLA-117's interim data suggest mild activity but insufficient for further enrollment. Both presentations will provide insights on T-cell engager development.
Merus N.V. (Nasdaq: MRUS) reported its Q1 2020 financial results, revealing a collaboration revenue decline to $6.3 million from $8.8 million year-over-year. The net loss increased to $16.5 million compared to $7.1 million in Q1 2019, reflecting higher operating expenses of $25.9 million, up from $18.5 million. Despite challenges from COVID-19, clinical trials for zenocutuzumab and other candidates remain on track, with an update expected by year-end. The company anticipates sufficient funds to support operations into 2022.